Faron Reports 18.7-Month Median OS in Wild-Type TP53 Patients

Faron said five abstracts were accepted for ASH 2026. In BEXMAB’s relapsed/refractory cohort after HMA failure, median overall survival was 18.7 months for patients with wild-type TP53, versus 10.9 months for monoallelic and 7.5 months for biallelic TP53 mutations.